{
  "success": true,
  "pagesUsed": [
    0,
    1,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ustekinumab (CNTO1275)",
        "type": {
          "id": "f1a019c6-58c6-4afc-b7cd-78fb9ca73c69",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "08ba6b5a-e194-479f-91f5-a79cf76ea613",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Fully human IgG1k monoclonal antibody to human IL-12/23p40.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "a6046caa-eb45-4fa8-8be5-bb398e109223",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "e4fe3dd0-dc32-40d2-b20a-53db40798d80",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching IV and SC placebo for blinding.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Oral 5-aminosalicylate (5-ASA)",
        "type": {
          "id": "ba243d97-137c-4318-a815-b0b293153c23",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "40e80543-72a0-4f86-9873-47d51ac15e7f",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be maintained at a stable dose through induction.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Oral corticosteroids",
        "type": {
          "id": "9d8d9251-e43a-4cee-b4d1-844e428d34c5",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "58a82441-1bda-4f8b-a9af-df90c7e73c6c",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Includes prednisone, budesonide, and beclomethasone dipropionate; stable dose required for induction.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Immunomodulators",
        "type": {
          "id": "fba20153-c484-40ab-b08b-f5a14871fe7b",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "9b830412-e4b8-4439-b0e3-be606650ea01",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX).",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "TNF-antagonist therapy",
        "type": {
          "id": "7b1efba3-226b-471d-9167-5726efbbb1f3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "65fb84d7-8b6b-4076-9da3-33efd46c2c71",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Infliximab, adalimumab, golimumab, or approved biosimilars; must be discontinued 8 weeks prior.",
        "administrationIds": [
          "admin_6"
        ]
      },
      {
        "id": "int_7",
        "name": "Vedolizumab",
        "type": {
          "id": "1460e79a-6db2-41f9-a0c2-f5b97411383b",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ad4c8948-006c-4aec-b260-7b8f5d3ceea7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-alpha4beta7 integrin antagonist; must be discontinued prior to study.",
        "administrationIds": [
          "admin_7"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ustekinumab IV",
        "administrableDoseForm": {
          "id": "5eea259d-438a-47d4-acf9-541bee75c39f",
          "code": "C42986",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Solution",
          "standardCode": {
            "id": "08e5bf47-c574-44d3-8e00-e56a8a035f55",
            "code": "C42986",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Solution",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "294be6b2-890a-4b4e-8d53-8321e4881907",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "130 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development"
      },
      {
        "id": "prod_2",
        "name": "Ustekinumab SC",
        "administrableDoseForm": {
          "id": "6dd4f06e-b106-4dac-b144-3ba629fcd224",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "92a98652-560b-4337-b5d6-c2b5a98f21e3",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "eccaa006-d962-48b3-84f3-2b45c10fd2e9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "90 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Induction Fixed Dose",
        "instanceType": "Administration",
        "dose": "130 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_2",
        "name": "Induction Weight-based (<=55 kg)",
        "instanceType": "Administration",
        "dose": "260 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_3",
        "name": "Induction Weight-based (>55 kg to <=85 kg)",
        "instanceType": "Administration",
        "dose": "390 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_4",
        "name": "Induction Weight-based (>85 kg)",
        "instanceType": "Administration",
        "dose": "520 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_5",
        "name": "Maintenance q8w",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Every 8 weeks",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Through Week 44"
      },
      {
        "id": "admin_6",
        "name": "Maintenance q12w",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Every 12 weeks",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Through Week 44"
      },
      {
        "id": "admin_7",
        "name": "Late Responder Induction",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Week 8 (for non-responders at Week 8)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ustekinumab",
        "instanceType": "Substance",
        "description": "Anti-IL-12/23p40 monoclonal antibody"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 7,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ustekinumab (CNTO1275)",
        "role": "Investigational Product",
        "description": "Fully human IgG1k monoclonal antibody to human IL-12/23p40."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching IV and SC placebo for blinding."
      },
      {
        "name": "Oral 5-aminosalicylate (5-ASA)",
        "role": "Background Therapy",
        "description": "Must be maintained at a stable dose through induction."
      },
      {
        "name": "Oral corticosteroids",
        "role": "Background Therapy",
        "description": "Includes prednisone, budesonide, and beclomethasone dipropionate; stable dose required for induction."
      },
      {
        "name": "Immunomodulators",
        "role": "Background Therapy",
        "description": "Azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX)."
      },
      {
        "name": "TNF-antagonist therapy",
        "role": "Concomitant Medication",
        "description": "Infliximab, adalimumab, golimumab, or approved biosimilars; must be discontinued 8 weeks prior."
      },
      {
        "name": "Vedolizumab",
        "role": "Concomitant Medication",
        "description": "Anti-alpha4beta7 integrin antagonist; must be discontinued prior to study."
      }
    ],
    "products": [
      {
        "name": "Ustekinumab IV",
        "doseForm": "Solution",
        "strength": "130 mg",
        "manufacturer": "Janssen Research & Development"
      },
      {
        "name": "Ustekinumab SC",
        "doseForm": "Injection",
        "strength": "90 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "substances": [
      {
        "name": "Ustekinumab",
        "description": "Anti-IL-12/23p40 monoclonal antibody"
      }
    ],
    "administrations": [
      {
        "name": "Induction Fixed Dose",
        "dose": "130 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (<=55 kg)",
        "dose": "260 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (>55 kg to <=85 kg)",
        "dose": "390 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (>85 kg)",
        "dose": "520 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Maintenance q8w",
        "dose": "90 mg",
        "frequency": "Every 8 weeks",
        "route": "Subcutaneous",
        "duration": "Through Week 44"
      },
      {
        "name": "Maintenance q12w",
        "dose": "90 mg",
        "frequency": "Every 12 weeks",
        "route": "Subcutaneous",
        "duration": "Through Week 44"
      },
      {
        "name": "Late Responder Induction",
        "dose": "90 mg",
        "frequency": "Once",
        "route": "Subcutaneous",
        "duration": "Week 8 (for non-responders at Week 8)"
      }
    ],
    "devices": []
  }
}